Celcuity (CELC) announced the completion of the submission of its new drug application to the FDA for gedatolisib in hormone receptor positive, human epidermal growth factor receptor 2 negative, advanced breast cancer. The NDA was submitted under the FDA’s Real-Time Oncology Review program, which is intended to facilitate shorter regulatory review periods.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity initiated with an Outperform at Wolfe Research
- Block upgraded, Dell downgraded: Wall Street’s top analyst calls
- Celcuity downgraded to Neutral from Buy at H.C. Wainwright
- Celcuity’s Gedatolisib: A Promising Standard for 2L Breast Cancer Treatment
- Celcuity Inc. Earnings Call: Strong Progress Amid Challenges